Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients

Inclusion Criteria: * Diagnosis of glaucoma or ocular hypertension in at least 1 eye. * Parent/legal guardian must provide informed consent, and children must agree to sign an approved assent form when applicable. * Must agree to comply with the requirements of the study and must be accompanied by a parent/guardian. * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Females of childbearing potential that are currently pregnant, have a positive result on a pregnancy test at the Screening Visit, intend to become pregnant during the study period, are breast feeding, or are not using birth control measures. * One sighted eye or monocular, including patients who cannot be dosed in both eyes for any reason. * History of chronic, recurrent or severe inflammatory eye disease. * Ocular trauma requiring medical attention within the past 3 months prior to the Screening Visit. * Ocular infection or ocular inflammation within the past 30 days prior to the Screening Visit. * Clinically significant or progressive retinal disease such as retinal degeneration, diabetic retinopathy, or retinal detachment. * Other severe ocular pathology (including severe dry eye), that in the opinion of the Investigator, would preclude the administration of a topical prostaglandin analogue. * Intraocular surgery within the past 30 days prior to the Screening Visit. * Any abnormality preventing reliable tonometry. * Any other conditions including severe illness which would make the …